Legend Biotech

Legend Biotech, founded in 2014, is a multinational biopharmaceutical company dedicated to discovering and developing cutting-edge cell-based therapies. The company has developed chimeric antigen receptor T (CAR-T) cell therapies targeting CD38 and B-cell maturation antigen (BCMA) for multiple myeloma, utilizing the patient's own immune cells, which are genetically modified ex vivo before being reinfused into the patient to precisely target and kill tumor cells. Leveraging its deep expertise in cell therapy and diverse research facilities, Legend Biotech aims to expand the application of cell therapies in treating difficult-to-cure diseases and autoimmune disorders.Legend Biotech’s first candidate product, LCAR-B38M, is a BCMA-directed CAR-T cell therapy. The novel dual-epitope design of the BCMA-targeting domain facilitates its tight binding to BCMA, which is highly expressed in primary myeloma cells and plasma cells. The company has partnered with Janssen Biotech, Inc., one of Johnson & Johnson's pharmaceutical companies, to develop and commercialize LCAR-B38M globally, with the product having advanced to Phase Ib/II studies.